|
Basic information |
| Metabolite name | Choline-containing compounds/(Creatine and Phosphocreatine) ratio |
 | N/A |
 |
N/A |
 |
N/A |
| Synonyms | Choline-containing compounds/(Creatine and Phosphocreatine) ratio |
| No. of studies | 49 |
|
Relationship between Choline-containing compounds/(Creatine and Phosphocreatine) ratio and depression (count: 49) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1050 | Type1 | MDD without gastrointestinal symptoms group vs. control group | Anterior cingulate gyrus | Human | Up |
| Study M1050 | Type1 | MDD with gastrointestinal symptoms group vs. control group | Putamen | Human | Up |
| Study M1050 | Type1 | MDD with gastrointestinal symptoms group vs. control group | Anterior cingulate gyrus | Human | Up |
| Study M1062 | Type1 | MDD without insomnia symptoms group vs. control group | Anterior cingulate cortex | Human | Up |
| Study M213 | Type1 | depression group vs. control group | Basal ganglia | Human | Down |
| Study M220 | Type1 | depression group vs. control group | Orbitofrontal cortex | Human | Up |
| Study M222 | Type1 | depression group vs. control group | Amygdala | Human | Down |
| Study M224 | Type1 | depression group vs. control group | Dorsolateral prefrontal cortex | Human | Up |
| Study M225 | Type1 | depression group vs. control group | Dorsolateral white matter | Human | Up |
| Study M228 | Type1 | depression group vs. control group | Frontal lobe | Human | Down |
| Study M232 | Type2 | ECS-treated LH group post-treatment vs. pre-treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M232 | Type3 | ECS-treated NLH group post-treatment vs. pre-treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M236 | Type3 | ECT-treated group post-treatment vs. pre-treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M238 | Type1 | depression group vs. control group | Putamen | Human | Up |
| Study M248 | Type1 | depression group vs. control group | Prefrontal cortex | Human | Up |
| Study M255 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Up |
| Study M257 | Type1 | depression group vs. control group | Thalamus | Human | Up |
| Study M263 | Type1 | acute and chronic depression group vs. control group | Prefrontal lobe | Human | Up |
| Study M265 | Type1 | unmedicated depression group vs. control group | Basal ganglia | Human | Up |
| Study M273 | Type2 | fluoxetine group post-treatment vs. pre-treatment | Frontal lobe | Human | Down |
| Study M273 | Type2 | EA + fluoxetine group post-treatment vs. pre-treatment | Frontal lobe | Human | Down |
| Study M273 | Type2 | EA + fluoxetine group post-treatment vs. pre-treatment | Hippocampus | Human | Up |
| Study M275 | Type1 | depression group vs. control group | Hippocampus | Human | Up |
| Study M275 | Type1 | depression group vs. control group | Thalamus | Human | Up |
| Study M275 | Type2 | paroxetine-treated depression group post-treatment vs. pre-treatment | Thalamus | Human | Down |
| Study M275 | Type2 | paroxetine-treated depression group post-treatment vs. pre-treatment | Hippocampus | Human | Down |
| Study M280 | Type1 | TBI with depression group vs. TBI without depression group | Basal ganglia | Human | Down |
| Study M281 | Type1 | depression group vs. control group | Hippocampus | Human | Up |
| Study M283 | Type2 | SSIR-treated responder group post-treatment vs. pre-treatment | Dorsolateral prefrontal cortex | Human | Up |
| Study M301 | Type1 | depression group vs. control group | Dorsolateral prefrontal white matter | Human | Down |
| Study M302 | Type1 | depression group vs. control group | Hippocampus | Human | Up |
| Study M302 | Type1 | depression group vs. control group | Striatum | Human | Down |
| Study M311 | Type1 | OSAHS group vs. control group | Frontal white matter | Human | Down |
| Study M319 | Type1 | depression group vs. control group | Prefrontal cortex | Human | Up |
| Study M320 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M321 | Type1 | depression group vs. control group | Prefrontal lobe white matter | Human | Down |
| Study M322 | Type1 | depression group vs. control group | Ventral prefrontal white matter | Human | Down |
| Study M322 | Type2 | paroxetine-treated depression group post-treatment vs. pre-treatment | Ventral prefrontal white matter | Human | Up |
| Study M326 | Type1 | depression group vs. control group | Caudate | Human | Up |
| Study M326 | Type2 | MBCT-treated depression group post-treatment vs. pre-treatment | Caudate | Human | Down |
| Study M326 | Type2 | MBCT-treated depression group post-treatment vs. pre-treatment | Putamen | Human | Down |
| Study M331 | Type1 | stroke with depression group vs. stroke without depression group | Cerebellum | Human | Up |
| Study M332 | Type1 | depression group vs. control group | Dorsolateral prefrontal white matter | Human | Down |
| Study M334 | Type1 | depression group vs. control group | Dorsal prefrontal cortex | Human | Up |
| Study M352 | Type1 | depression group vs. control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M352 | Type1 | depression group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M354 | Type1 | depression group vs. control group | Mesial temporal lobe | Human | Up |
| Study M356 | Type2 | mirtazapine-treated depression group post-treatment vs. pre-treatment | Hippocampus | Human | Down |
| Study M449 | Type1 | stroke with depression group vs. stroke without depression group on 14th day after stroke | Cerebellum | Human | Up |
| Study M468 | Type1 | depression group vs. control group | Prefrontal cortex | Human | Up |
| Study M468 | Type1 | depression group vs. control group | Hippocampus | Human | Up |
| Study M468 | Type2 | depression group post-exercise vs. pre-exercise | Hippocampus | Human | Down |
| Study M580 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M580 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M612 | Type1 | MDD group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M638 | Type1 | MDD group vs. control group | Lentiform nucleus | Human | Up |
| Study M638 | Type1 | MDD group vs. control group | Cerebellum | Human | Up |
| Study M638 | Type1 | MDD group vs. control group | Anterior cingulate cortex | Human | Up |
| Study M638 | Type1 | MDD group vs. control group | Thalamus | Human | Up |
| Study M638 | Type1 | MDD group vs. control group | Prefrontal white matter | Human | Up |
| Study M660 | Type1 | ESRD with depression vs. ESRD without depression | Frontal lobe | Human | Up |
| Study M733 | Type3 | fluoxetine group vs. control group, day 1 | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M752 | Type1 | PSD group vs. control group | Hippocampus | Wistar rat | Up |
| Study M752 | Type2 | PSD + Yi-nao-jie-yu decoction group vs. PSD group | Hippocampus | Wistar rat | Down |
| Study M812 | Type1 | MDD group vs. control group | Hippocampus | Human | Down |
| Study M855 | Type1 | MDD group vs. control group | Putamen | Human | Up |
| Study M895 | Type1 | MDD without childhood trauma group vs. control group | Putamen | Human | Up |
| Study M895 | Type1 | MDD with childhood trauma group vs. control group | Cerebellum | Human | Down |
| Study M895 | Type1 | MDD without childhood trauma group vs. control group | Anterior cingulate cortex | Human | Up |
| Study M895 | Type1 | MDD without childhood trauma group vs. control group | Cerebellum | Human | Down |
| Study M895 | Type1 | MDD with childhood trauma group vs. control group | Putamen | Human | Up |
| Study M895 | Type1 | MDD with childhood trauma group vs. control group | Anterior cingulate cortex | Human | Up |
| Study M899 | Type1 | depression without non-suicidal self-injury group vs. control group | Thalamus | Human | Up |
| Study M954 | Type2 | modified electroconvulsive therapy group vs. control treatment group | Prefrontal white matter and anterior cingulate cortex | Human | Down |
| Study M960 | Type1 | olfactory-bulbectomised group vs. control group | Hippocampus | Wistar rat | Down |